Food and Drug Administration Commissioner Scott Gottlieb, M.D., yesterday announced the agency’s 2019 agenda to address the opioid epidemic. Among other actions, the agency is considering using its authority under the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018 to mandate short-duration packaging for outpatient dispensing of certain solid, oral dosage forms of immediate-release opioid analgesics to treat acute pain, and require manufacturers to develop technologies such as mail-back pouches to dispose of unused opioid medications. FDA also plans to announce changes to strengthen the Risk Evaluation and Mitigation Strategy for transmucosal immediate-release fentanyl medicines, and issue updated guidance to promote the development of non-opioid drugs to treat pain.

Related News Articles

Headline
The Health Resources and Services Administration yesterday awarded 120 organizations, including hospitals, $200,000 each to develop community partnerships and…
Headline
Laws that allow pharmacists to dispense the opioid antidote naloxone without a physician’s prescription are associated with a sharp reduction in fatal opioid-…
Headline
The White House Office of National Drug Control Policy seeks by 2022 to reduce drug overdose deaths and youth illicit drug use by 15 percent and opioid…
Perspective
Investing in our country’s health infrastructure is the right move to make.
Headline
The AHA yesterday announced support for the Opioid Workforce Act of 2019, bipartisan legislation to reduce the nation’s shortage of opioid treatment providers…
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic, of which the AHA is a sponsor, held a two-day meeting this week…